The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that “understanding and supporting the Hungarian government's efforts to reduce the burden on patients, voluntarily restricts the price of its non-prescription product Panangin®, a magnesium and potassium dietary supplement and complementary treatment for chronic heart disease and cardiac […]
The consolidated revenue of Gedeon Richter Plc. was HUF 224 billion in the first quarter, up 10% year-on-year, the pharmaceutical company announced on the website of the Budapest Stock Exchange (BSE) on Tuesday. The company posted a profit after tax of HUF 68.1 billion in the first quarter, similar to the previous year. According to […]
The pharmaceutical company Richter Gedeon Plc.'s new central office building, the Richter Center, situated in Budapest's 10th District, has received prestigious real estate market recognition, winning the Headquarters of the Year Award in the 2025 Office of the Year competition, the company told MTI on Friday. The statement said that the 17,400-square-meter, six-story headquarters building, […]
Budapest-based pharmaceutical company Gedeon Richter Plc. has received positive opinion from CHMP for marketing authorization for Junod and Yaxwer, its biosimilar denosumab products for bone disease and osteoporosis. Budapest-based pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that it received a positive opinion from the Committee for Medicinal […]
The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that the European Medicines Agency (EMA) has accepted Richter’s marketing authorization application (MAA) for its proposed biosimilar to RoActemra tocilizumab. Tocilizumab, the first biologic to inhibit IL-6 signaling, is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic […]
Budapest-based pharmaceutical giant Gedeon Richter Plc. announced its Q4/FY 2024 financial results at the website of the Budapest Stock Exchange by stating that 2024 was an active year with business development across all segments, aimed at providing access to health by bringing solutions to unmet needs and by offering affordable medicines to a wide range […]
Gedeon Richter has announced positive topline results from Phase I and Phase III clinical studies for its proposed biosimilar to RoActemra® tocilizumab that has the development code 'RGB-19'. The Hungarian pharmaceutical firm points out in a statement on the webiste of the Budapest Stock Exchange that Phase I clinical study evaluated the equivalence of pharmacokinetics […]
Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that on December 16, 2024 – according to its program related to employee share bonuses – 206,546 treasury shares were granted to 4,974 employees. Until January 1, 2027 the shares will be held in deposit on the employee’s securities accounts kept by […]
Gedeon Richter Plc. and Hikma Pharmaceuticals Plc. has announced that the U.S. Food and Drug Administration (FDA) had accepted for review the Biologics License Applications (BLA) for RGB-14, a Denosumab biosimilar candidate comprising two biosimilar products referencing Prolia® and Xgeva®, a human monoclonal antibody for the treatment of osteoporosis and fractures due to bone metastasis, […]
Consolidated sales of Richter Gedeon Plc. amounted to HUF 636.4 billion in the first nine months, up 5.7% year-on-year, the pharmaceutical company announced on the website of the Budapest Stock Exchange on Tuesday. The company posted a 42.2% increase in profit after tax to 175.9 billion forints in the first three quarters. The report underlined […]
On Friday, the Budapest Stock Exchange (BSE) commemorated the 30th anniversary of the listing of the pharmaceutical giant Richter Gedeon Plc. with a ceremonial opening bell Participation on the stock market has made a significant contribution to the success of the pharmaceutical company both at home and abroad, a BSE statement to MTI said, explaining […]
The pharma companies AbbVie (headquartered in North Chicago, Illinois in the United States) and Gedeon Richter Plc. (headquartered in Budapest, Hungary) have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. A statement on the website of the Budapest Stock Exchange highlights that this collaboration […]
Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Gedeon Richter have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to Stelara, it was announced on the website of the Budapest Stock Exchange. Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply […]
The Centenary Foundation of Richter Gedeon Plc., a Budapest-based pharmaceutical company, will provide HUF 100 million in grants to public educational institutions for the development of equipment and technical conditions necessary for the teaching of natural sciences, the company told MTI on Monday. According to the statement, the foundation first published its call for the […]
The new headquarters of Richter Plc. in Kőbánya, the 10th district of the Hungarian capital was inaugurated on Thursday. The 17,400-square-meter building, which provides space for 450 employees, was completed with an investment of HUF 20 billion, financed by the pharmaceutical company from its own resources. Speaking at the opening ceremony, Energy Minister Csaba Lantos […]
